https://orcid.org/0000-0001-8964-1653
References
- O’Donnell JC. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research. Value Health. 2013;16(6):S1–S3.
- Degtiar I. A review of international coverage and pricing strategies for personalized medicine and orphan drugs. Health Policy. 2017;121(12):1240–1248.
- Gavan SP, Thompson AJ, Payne K. The economic case for precision medicine. Expert Rev Precis Med Drug Dev. 2018;3(1):1–9.
- Janiaud P, Serghiou S, Ioannidis JP. New clinical trial designs in the era of precision medicine: an overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treat Rev. 2019;73:20–30.
- US Food and Drug Administration. Master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics guidance for industry; 2018.
- Renfro L, Sargent D. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol. 2017;28(1):34–43.
- US Food and Drug Administration. Guidance for industry, clinical trial endpoints for the approval of cancer drugs and biologics; 2007.
- Cunanan KM, Iasonos A, Shen R, et al. An efficient basket trial design. Stat Med. 2017;36(10):1568–1579.
- Ramaekers BL, Joore MA, Grutters JP. How should we deal with patient heterogeneity in economic evaluation: a systematic review of national pharmacoeconomic guidelines. Value Health. 2013;16(5):855–862.
- Saramago P, Espinoza MA, Sutton AJ, et al. The value of further research: the added value of individual-participant level data. Appl Health Econ Health Policy. 2019;17(3):273–284.
- Sculpher M, Gafni A. Recognizing diversity in public preferences: the use of preference sub‐groups in cost‐effectiveness analysis. Health Econ. 2001;10(4):317–324.